AIDS associated myelopathy therapy - Genopia Biomedical

Drug Profile

AIDS associated myelopathy therapy - Genopia Biomedical

Latest Information Update: 24 Feb 2010

Price : $50

At a glance

  • Originator GENOPIA Biomedical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord disorders

Highest Development Phases

  • Discontinued Spinal cord disorders

Most Recent Events

  • 24 Feb 2010 Discontinued - Phase-II for Spinal cord disorders in Germany (unspecified route)
  • 10 Aug 2004 Genopia's compound is available for licensing (http://www.genopia.de)
  • 10 Aug 2004 Orphan Drug Status for AIDS associated myelopathy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top